ABUS — Arbutus Biopharma Share Price
Last trade - 00:00- $415.28m
- $293.87m
- $6.91m
- 27
- 10
- 77
- 34
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.19 | ||
| Price to Tang. Book | 3.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 40.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.4% | ||
| Return on Equity | -76.19% | ||
| Operating Margin | -678.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.49 | 10.7 | 5.95 | 6.01 | 6.91 | 10.67 | 13.94 | -21.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to provide a curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. The Company’s two lead product candidates are AB-729, its subcutaneously-delivered RNA interference (RNAi) product candidate that suppresses HBsAg expression, and AB-836, the Company’s next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is in an ongoing Phase Ia/Ib clinical trial and a Phase IIa proof-of-concept clinical trial in collaboration with Assembly Biosciences, Inc.
Directors
- Frank Torti NEC (42)
- William Collier PRE (61)
- David Hastings CFO (59)
- Elizabeth Howard EVP (67)
- Michael Sofia CSO (63)
- Michael McElhaugh OTH (47)
- Gaston Picchio OTH (58)
- Daniel Burgess IND (59)
- Andrew Cheng IND (55)
- Richard Henriques IND (65)
- Keith Manchester IND (52)
- James Meyers IND (55)
- Tram Tran IND
- Eric Venker IND (34)
- Last Annual
- December 31st, 2020
- Last Interim
- September 30th, 2021
- Incorporated
- January 1st, 2018
- Public Since
- November 13th, 2010
- No. of Shareholders
- 102
- No. of Employees
- 78
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 135,269,247
- Address
- 701 Veterans Circle, WARMINSTER, 18974
- Web
- http://www.arbutusbio.com/
- Phone
- +1 2674690914
- Auditors
- Ernst & Young LLP
Latest News for ABUS
Upcoming Events for ABUS
Q4 2021 Arbutus Biopharma Corp Earnings Release
Q1 2022 Arbutus Biopharma Corp Earnings Release
Arbutus Biopharma Corp Annual Shareholders Meeting
Similar to ABUS
Abcam
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amryt Pharma
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
As of Today at 12:05 UTC, shares in Arbutus Biopharma are trading at $3.07. This share price information is delayed by 15 minutes.
Shares in Arbutus Biopharma last closed at $3.07 and the price had moved by -21.48% over the past 365 days. In terms of relative price strength the Arbutus Biopharma share price has underperformed the S&P500 Index by -36.03% over the past year.
The overall consensus recommendation for Arbutus Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Arbutus Biopharma does not currently pay a dividend.
Arbutus Biopharma does not currently pay a dividend.
Arbutus Biopharma does not currently pay a dividend.
To buy shares in Arbutus Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.07, shares in Arbutus Biopharma had a market capitalisation of $415.28m.
Here are the trading details for Arbutus Biopharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABUS
Based on an overall assessment of its quality, value and momentum Arbutus Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Arbutus Biopharma is $6.30. That is 105.21% above the last closing price of $3.07.
Analysts covering Arbutus Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.86 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arbutus Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +3.37%.
As of the last closing price of $3.07, shares in Arbutus Biopharma were trading -10.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arbutus Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arbutus Biopharma's management team is headed by:
- Frank Torti - NEC
- William Collier - PRE
- David Hastings - CFO
- Elizabeth Howard - EVP
- Michael Sofia - CSO
- Michael McElhaugh - OTH
- Gaston Picchio - OTH
- Daniel Burgess - IND
- Andrew Cheng - IND
- Richard Henriques - IND
- Keith Manchester - IND
- James Meyers - IND
- Tram Tran - IND
- Eric Venker - IND